

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Commissioner for Patents, Mail Stop: Patent Applications PO Box 1450, Alexandria, VA 22313-1450 on this 25th day of November 2002.
s/ 
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
J. Stjernschantz, et al.

Serial No.: Not Yet Assigned (Continuation of 10/330,846, Filed on 12/27/2002)

Filed: Herewith

For: PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION

Group Art Unit: Not Yet Assigned (Formerly 1626)

Examiner: Not Yet Assigned (Formerly Robert Gerstl)

Mail Stop: Patent Application
Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the documents listed on the attached substitute Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified in 37 CFR 1.97(b)--i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached substitute Form PTO-1449 and returning a copy of the initialed form to the Applicant.

Copies of the cited documents are not enclosed since they were previously cited by or submitted to the PTO in Application Serial No. 10/330,846, filed December 27, 2002, upon which the present application relies for priority benefit under 35 USC 120.

If any fees are due in connection with the filing of this statement, including the fee set forth in

PC30246J
Information Disclosure Statement

37 CFR 1.17(p) in the event that the period specified in 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Date:

11/25/2003

Pharmacia Aktiebolag/A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7320
Fax: (858) 678-8233

Respectfully submitted,


Joseph F. Reidy
Attorney For Applicant
Registration No. 39,340

Form 1449

ATTY. DOCKET NO.
PC 30246.JSERIAL NO.
To be assigned**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**APPLICANT
Stjernschantz et al.

FILING DATE

Herewith - 11/25/2003 To be assigned

GROUP

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	3,956,284	5/11/76	Hess et al.	260	240R	
	3,962,312	6/8/76	Hayashi et al.	260	468D	
	3,987,087	10/19/76	Bundy			
	4,001,300	1/4/77	Axen			
	4,011,262	3/8/77	H-J. E. Hess et al.	260	520 B	
	4,115,586	9/19/76	Miller, Jr.			
	4,116,988	9/26/78	N.A. Nelson	260	413	
	4,117,119	9/26/78	Kurono et al.	424	180	
	4,128,713	12/5/78	Schneider	542	426	
	4,131,738	12/26/1978	Smith	560	121	
	4,599,353	7/8/86	Bito	514	530	
	4,820,728	4/11/89	Collins et al.	514	530	
	4,824,857	4/25/89	Goh et al.	514	398	
	4,883,819	11/28/89	Bito	514	573	
	5,001,153	3/19/91	Ueno et al.	514	530	9/18/88
	5,057,621	10/15/91	Cooper et al.	560	53	7/31/84
	5,151,444	9/29/92	Ueno et al.	514	530	9/18/88
	5,166,178	11/1992	Ueno	514	573	
	5,194,429	3/1993	Ueno	514	63	
	5,422,368	06/1995	Stjernschantz	514	530	
	5,296,504	03/1994	Stjernschantz	514	530	
	5,321,128	06/1994	Stjernschantz	514	530	
	5,422,369	06/1995	Stjernschantz	514	530	
	6,187,813	02/2001	Stjernschantz	514	530	
	6,030,999	02/2000	Stjernschantz	514	530	

- If pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE*	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	573,018	2/6/86	AU	C07C	177/00		
	600,168	8/2/90	AU	A61K	031/557		
	986,926	4/6/76	CA				
	2,234,709	2/1/73	DE	C07C	57/02		
	170,258	2/5/86	EPO	C07C	177/00		
	238,135	8/1988	EPO				
	242,580	10/28/87	EPO	A61K	31/557		
	253,094	1/20/88	EPO	A61K	31/557		
	281,239	9/7/88	EPO	C07C	177/00		
	289,349	11/2/88	EPO	C07C A61K	177/00 31/557		
	308,135	3/22/89	EPO	A61K	31/557 9/06		
	364,417	4/18/90	EPO	A61K	31/557		
	366,279	5/2/90	EPO	A61K	31/557		
	455264 A2	11/6/91	EPO	A61K	31/557		
	WO90/02553	3/1990	WO	C07C	61/100		
	1,324,737	7/25/73	UK	C07C	61/00		

* Publication date, unless otherwise indicated

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Bill A (1975) "Blood Circulation and fluid dynamics in the eye". <i>Physiol. Rev.</i> 55: 383-417
		Bito LZ, Draga A, Blanco DJ, Camras CB (1983) "Long Term Maintenance of Reduced intraocular Pressure by Daily or Twice Daily Topical Application of Prostaglandins to Cat or Rhesus Monk,ey Eyes" <i>Invest. Ophthalmol. Vis. Sci.</i> 24: 312-319
		Bito, Baroody and Miranda (1987): Eicosanoids as a new class of ocular Hypotensive agents. The apparent therapeutic advantage of derived Prostaglandins of the A and B type as compared with primary prostaglandins of the E, F and D types", <i>Experimental Eye Research</i> , 44:825.
		Bito LZ, Camras CB, Gum GG and Resul B (1989). "The Ocular Hypotensive Effects and Side Effects of Prostaglandins on the Eyes of Experimental Animals" <i>Progress in Clinical and Biological Research</i> 312 Ed. L.Z. Bito and Johan Stjernschantz, A.R. Liss, Inc., New York.
		Burke et l., "Prostaglandin F _{2α} Effects on Rabbit IOP Negatively Correlate with Classical PGF _{2α} -Receptor Stimulation Presented at ARVO annual meeting in Florida May 1-6, 1988
		Bundy, Chem Abst. 90:168141d, 1979
		Camras CB, Bito LZ (1981). Reduction of intraocular pressure in normal and glaucomatous primate (<i>Aotus trivirgatus</i>) eyes by topically applied prostaglandin F _{2α} . "Curr Eye Res 1:205-209
		Camras, CB, Podos SM, Rosenthal JS, Lee PY, Severin CH (1987a). Multiple dosing of prostaglandin F _{2α} or epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics. <i>Invest Ophthalmol Vis Sci</i> 28:463-469.
		Camras C B, Bito L Z and Eakins K E (1977): "Reduction of intraocular pressure by prostaglandins applied to the eyes of concious rabbits", <i>Invest Ophthalmol Vis. Sci.</i> 16:1125.
		Camras CB, Bhuyan KC, Podos SM, Bhuyan DK Master RWP (1987b) "Multiple Dosing of Prostaglandin F _{2α} or epinephrine on cynomolgus mokey eyes. II. Slitlamp biomicroscopy, aqueous humor analysis, and fluorescein angiography." <i>Invest. Ophthalmol. Vis. Sci.</i> 28: 921-926

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Camras CB, Siebold EC, Lustgarten JS, Serle JB, Frisch SC, Podos SM, Bito LZ (1988) "Reduction of IOP by prostaglandin F _{2α} -1-isopropyl ester topically applied in glaucoma patients", <u>Ophthalmology</u> 95(Suppl.) 129 [This article is referenced in the specification, and was raised as prior art in an opposition to Australian patent application 625096, which is related to the instant application. However, we have been unable to locate a copy of this article.]
		Crawford K, Kaufman PL and True Gabel, BA (1987), "Pilocarpine antagonizes PGF _{2α} -induced ocular hypotension: Evidence for enhancement of uveoscleral outflow of PGF _{2α} ." <u>Invest. Ophthalmol. Vis. Sci. (Supp.) ARVO Abstracts</u> 11
		Crawford, K and Kaufman, P.L., (1987) "Pilocarpine Antagonizes Prostaglandin F _{2α} -Induced Ocular Hypotension in Monkeys" <u>Arch. Ophthalmology</u> 105 1112
		Flach AJ, Elisason JA (1988). "Topical prostaglandin E ₁ effects on normal human intraocular pressure. <u>J. Ocu. Pharmacol.</u> 4:13-18
		Gabelt, B. and Kaufman, P.L., (1989)"Prostaglandin F _{2α} Increases Uveoscleral Outflow in the Cynomolgus Monkey", <u>Exp. Eye Res.</u> 49 389-402
		Giuffré G. (1985). "The effects of prostaglandin F _{2α} in the human eye." <u>Graefes Arch Clin. Exp. Ophthalmol.</u> 222:139-141
		Goldberg I, Kolker A.E., Kass M.A. and Becker B (1980) "Dipivefrin: current concepts", <u>Australia J. Ophthalmol.</u> , 8:147
		Granstrom, E., (1975) "Metabolism of 17-Phenyl-18,19,20-Trinor-Prostaglandin F _{2α} in the Cynomolgus Monkey and the Human Female", <u>Prostaglandins</u> 9:19-45.
		Kass, M.A., Posos, S.M., Moses, R.A., and Becker B. (1972): Prostaglandin E1 and aqueous humor dynamics", <u>Invest Ophthalmol.</u> 11:1022
		Kass M.A., Mandell AI, Goldberg I, Paine J.M. and Becker B (1979) "Dipivefrin and epinephrine treatment of elevated intraocular pressure: A comparative study", <u>Arch Ophthalmol.</u> 97:1865
		Kaufman PL (1986). "Effects on intracamerally infused prostaglandins on outflow facility in cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle." <u>Exp. Eye Res.</u> 43:819-827
		Kerstetter J R, Brubaker R F, Wilson S E and Kullerstrand B S (1987): "Prostaglandin F2 alpha 1-isopropyl ester effects on aqueous humor dynamics in human subjects", <u>Invest Ophthalmol Vis Sci Suppl.</u> 28:266.
		Kerstetter J R, Brubaker R F, Wilson S E and Kullerstrand L (1988) "Prostaglandin F2α-1- Isopropylester Lowers Intracolor Pressure Without Decreasing Aqueous Humor Flow". <u>Am. J. Ophthalmology</u> 105:30-34.
		Kirk-Othmar "Encyclopedia of Chemical Technology", 3d Ed. Supplement Volume 711-752 (1984)
		Lee, P-Y, Shae H, XZu L, Qu C-K (1988). The effect of prostaglandin F _{2α} on intraocular pressure in normotensive human subjects." <u>Invest. Ophthalmol. Vis. Sci.</u> 29:1474-1477
		Miller, "Biological Activities of 17-phenyl-18,19,20-trinorprostaglandins", <u>Prostaglandins</u> 9 9-18 (1975)
		Nilsson SFE, Stjernschantz J and Bill A (1987) "PGF _{2α} increase uveoscleral outflow. <u>Invest. Ophthalmol Vis. Sci. Suppl.</u> 284
		Ritch, Shields and Krupin (1989): "The Glaucomas", C V Mosby, p 561.
		Starr, M.S. (1971) "Further studies on the effect of prostaglandin on intraocular pressure in the rabbit, <u>Exp. Eye, Res.</u> 11:170
		Villumsen J, Alm A, Soderstrom M, (1989) "Prostaglandin F2α-isopropylester Eye Drops: Effect on Intraocular Pressure in Open Angle Glaucoma". <u>Brit. J. Ophthalmology</u> 73, 975-79.
		Villumsen J. Alm A (1989) "Prostaglandin F _{2α} isopropylester eye drops. Effects in normal human eyes." <u>Br. J. Ophthalmol.</u> 73:419-426
		Villumsen J and Alm A (1987): "The effect of prostaglandin F2α eye drops in open angle glaucoma", <u>Invest Ophthalmol. Vis. Sci.</u> 28:378
		Wang R-F, Camras C.B., Lee P-Y, Podos S.M. and Bito LZ (1987) "The ocular hypotensive effects of Prostaglandins F2α isopropyl ester and A2 in glaucomatous monkeys <u>Invest Ophthalmol Vis Sci ARVO Supl.</u> 28:266
		Yankee, Chem Abst. 88:62048, 1978
		Woodward et al., "Prostaglandin F _{2α} Effects on IOP Negatively Correlate with Classical PGF _{2α} -Receptor Stimulation Presented in Eighty International Congress of Eye Research in San Francisco Sept. 4-8, 1988

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Woodward et al. (1989) "Prostaglandin F _{2α} Effects on Intraocular Pressure Negatively Correlate with FP-Receptor Stimulation" <i>Invest. Ophthal.</i> 30 (8) 1838-1842
	Supplement to Investigative Ophthalmology and Visual Science 22 39 (1982), L.Z. Bito, A. Draga, J. Blanco, and C.B. Camras, "Maintenance of Reduced Intraocular Pressure (IOP) for several months by topical application of prostaglandin (PG) E ₁ to Eyes of Trained Cats"
	Abstracts 12 and 13 on page 325 of ARVO Annual Meeting Abstract Issue 1988 of Annual Meeting: Sarasota, Florida May 1-6, 1988
	Abstracts 31, 33 and 35 on page 35 of ABSTRACTS 8th International Congress of Eye Research, San Francisco, September 4-8, 1988
	Journal of Medicinal Chemistry, volume 23, 1980, pages 525-35
	Annual Reports in Medicinal Chemistry, volume 11, 1976, pages 80-88
	Zajacz: IRCS Medical Science: Clinical Medicine; Clinical Pharmacology and Therapeutics: Drug Metabolism and Toxicology; The Eye: Reproduction, Obstetrics and Gynecology, volume 4, 1976, page 316
	Miranda and Bito: The Ocular Effects of Prostaglandins and Other Eicosanoids, 1989, pages 171-195
	ASPET abstract: Pharmacologist, volume 29, 1987, page 139, 33/187
	Investigative Ophthalmology & Visual Science, volume 31, 1990, pages 2560-2567
	The Ocular Effects of Prostaglandins and Other Eicosanoids, 1989, page 179
	Journal of Ocular Pharmacology, volume 9, 1991, page 189
	The Association for Research in Vision and Ophthalmology, Annual Spring Meeting, Sarasota, FL, May 1-6, 1988: Investigative Ophthalmology & Visual Science, volume 29, supplement page 325, abstracts 12 and 13
	Prostaglandins and Medicine, 3, 1979, pages 33-37
	Bito: Experimental Eye Research, volume 39, 1984, pages 807-829
	Archives of Ophthalmology, vol 105, 1987, pages 1036-1039
	Archives of Ophthalmology, volume 106, 1988, pages 449-450
	The Ocular Effects of Prostaglandins and Other Eicosanoids, 1989, pages 349-368
	Investigative Ophthalmology & Visual Science, volume 25, 1984, 1087-93
	Prostaglandins, volume 12, 1976, pages 493-500
	Prostaglandins, volume 10, 1975, pages 5-18
	Arch. Ophthalmol. - Vol. 105, February 1987, 249-252
	Exp. Eye Res. (1984) 38, 181-194
	Exp. Eye Res. (1987) 44, 825-837
	ARVO abstracts 266, 5

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

NY1-O:\SJL\PU25\102688Form PU25 last updated